间充质干细胞治疗脓毒症的研究进展

Research progress of mesenchymal stem cell therapy for sepsis

脓毒症是一种严重的、威胁生命的炎症反应综合征,目前仍以对症支持治疗为主。因此,亟需寻找一种新的治疗策略以改善脓毒症患者预后。间充质干细胞(mesenchymal stem cells, MSCs)因其独特的生物学特性,备受生命科学及医学领域研究者青睐。近年来,多项研究表明MSCs可通过调节免疫状态、平衡炎症反应、降低细菌负荷、改善器官功能等途径,进而提高脓毒症机体的生存率,这表明MSCs有望成为脓毒症治疗新策略。本文就MSCs在脓毒症临床前与临床研究中的最新进展作一综述。

Sepsis is a serious and life-threatening inflammatory response syndrome, which is still treated mainly by symptomatic support. Therefore, there is an urgent need to find a new treatment strategy to improve the prognosis of patients with sepsis. Mesenchymal stem cells(MSCs) are favored by researchers in the field of life science and medicine because of their unique biological characteristics. In recent years, many studies have shown that MSCs can improve the survival rate of sepsis by regulating immune state, balancing inflammatory response, reducing bacterial load and improving organ function, which indicates that MSCs is expected to be a new strategy for the treatment of sepsis. This article reviews the latest progress of MSCs in preclinical and clinical study of sepsis.